From July to September, our research team reviewed published clinical trial data, peer-reviewed meta-analyses, and federal treatment statistics. The naltrexone implant success rate runs from approximately 80% abstinence at 3 months during active coverage to 53% at 6 months in randomized controlled trials, compared to 16% for oral naltrexone and 11% for placebo in the same studies. The central variable is coverage: outcomes during an active implant are substantially higher than outcomes after a single implant course ends, and continuous implant therapy produces the strongest long-term results across published research.

This report breaks down naltrexone implant success rates by outcome metric, time point, naltrexone format, clinical profile, plus Michigan opioid treatment context.

Naltrexone Implant Success Rate by Outcome Metric: 2026

The table below breaks down the primary success metrics published across controlled trials and cohort studies of naltrexone implant therapy for opioid dependence.

Outcome Metric Published Rate
6-week abstinence (during active coverage) ~100%
3-month abstinence (during active coverage) ~80%+
Relapse rate during active implant coverage ~1.3%
6-month abstinence (implant group, RCT) ~53%
6-month abstinence (oral naltrexone group, same RCT) ~16%
6-month abstinence (placebo group, same RCT) ~11%
12-month continuous abstinence (single implant course) ~7%
12-month abstinence (ongoing implant therapy, clinic audit) ~80%
Treatment retention at 6 months vs. oral naltrexone ~2x higher
Retention benefit vs. placebo (meta-analysis odds ratio) 1.86 (injectable/implant)

The data reveals that outcomes during active implant coverage are dramatically higher than outcomes after a single course ends without continuation. The drop from ~53% at 6 months to ~7% continuous abstinence at 12 months following one implant course points to a clear pattern: the implant works while it is in place, and patients who do not continue treatment lose that protection. Ongoing therapy, rather than a single course, is the mechanism behind the 80% 1-year abstinence figure reported by specialized implant clinics.

Naltrexone Implant Success Rate by Time Point: 2026

The table below breaks down published abstinence rates at each follow-up interval, comparing implant outcomes to oral naltrexone and placebo from the same randomized controlled trial data.

Time Point Implant Oral Naltrexone Placebo / No Medication
6 weeks ~100% (during coverage) Lower ~20%
3 months ~80%+ (during coverage) ~35-40% ~20-25%
6 months ~53% ~16% ~11%
12 months (single course only) ~7% ~5-10% ~5-10%
12 months (ongoing implant therapy) ~80% N/A N/A

The data reveals that the implant’s advantage over oral naltrexone is strongest during the coverage window, where compliance is removed as a variable entirely. After a single 6-month implant course ends, outcomes converge with other approaches, confirming that the mechanism of benefit is continuous receptor blockade, not a one-time treatment effect.

Naltrexone Implant Success Rate vs. Other Naltrexone Formats: 2026

The table below compares the naltrexone implant to extended-release injectable naltrexone (Vivitrol) and daily oral naltrexone across the key dimensions that determine real-world outcomes.

Format Coverage Per Dose 6-Month Abstinence Compliance Dependency US FDA Status
Naltrexone implant 2 to 6 months (formulation-dependent) ~53% None Not FDA-approved in implant form
XR injectable naltrexone (Vivitrol) ~1 month ~36% Low (monthly clinic visit) FDA-approved
Oral naltrexone (daily pill) 24 hours ~16-25% High (daily adherence required) FDA-approved

The data shows that the naltrexone implant outperforms both oral and injectable formats at the 6-month mark, with the compliance advantage growing over time as oral adherence rates decline. Vivitrol occupies the middle ground, removing the daily pill burden while requiring monthly return visits for injection. The implant’s longer coverage window means fewer decision points for the patient during the highest-risk months of early recovery. Implants are not currently FDA-approved in the United States in this form, and their availability varies by facility.

Naltrexone Implant Clinical Profile: 2026

The table below breaks down the clinical characteristics and patient selection factors associated with naltrexone implant therapy.

Factor Detail
Administration Subcutaneous insertion under local anesthesia
Coverage duration per implant 2 to 6 months; some formulations up to 9 months
Mechanism Continuous opioid receptor blockade; prevents euphoric effect of opioid use
Required pre-condition Full opioid detox; typically 7 to 10 days opioid-free before implant
Best-fit patient profile Post-detox, motivated patients; prior oral naltrexone failure
Contraindications Active opioid use, acute hepatitis or liver failure, pregnancy
Recommended follow-up Continued therapy after first implant course for sustained outcomes
US regulatory status Not FDA-approved in implant form; oral and injectable (Vivitrol) are FDA-approved

The data shows that patient selection and pre-implant detox are the two clinical factors most directly linked to implant outcomes in published research. Patients who are fully detoxed and opioid-free before implant insertion achieve the highest early abstinence rates, while those with incomplete detox or continued opioid exposure at the time of insertion show reduced efficacy. Continued therapy after the first course is the strongest predictor of 12-month outcomes across all reviewed studies.

Michigan Opioid Treatment Context: 2026

The table below breaks down Michigan’s current opioid use disorder and treatment landscape, providing context for the scale of need that drives demand for extended-release options like the naltrexone implant.

Metric Michigan Data
Adult OUD prevalence 3.2% (vs. 2.5% national average)
Opioid overdose deaths, 2024 1,342 (down 41% from 2,287 in 2023)
Projected overdose death rate, 2025 16.4 per 100,000 (down from 30.8 in 2021)
Fentanyl share of overdose deaths 68%
OUD patients receiving timely evidence-based care 35%
Adults nationally receiving MOUD after detox 25%
Oral naltrexone adherence rates in real-world settings Significantly below controlled trial rates

The data shows that Michigan’s treatment gap, where 65% of OUD patients are not receiving timely evidence-based care, creates direct demand for treatment formats that do not rely on daily patient decision-making. Extended-release options including the naltrexone implant directly address the adherence problem that makes oral naltrexone less effective in real-world settings. Michigan’s fentanyl-dominated drug supply makes the post-detox coverage window more critical than in prior eras, as relapse into fentanyl use carries higher overdose risk than relapse into prescription opioids.

Contact All Opiates Detox

For more information about opiate detox and naltrexone treatment options in Wyandotte, Michigan, contact All Opiates Detox.

Contact All Opiates Detox to speak directly with Dr. Joseph George, MD, at (800) 458-8130.

Sources